LLA.L,0P0001T9GN,0 (LLA) Share Price, News & Analysis

Company Overview

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,500 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:LLA
• CIK: N/A
• Web: lunglifeai.com
• Phone: (805) 409-9868
• Fax: N/A
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£4.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.59%
• Return on Assets: -27.28%

Debt

• Debt-to-Equity Ratio: 2.66
• Current Ratio: 2.83
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 28 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: -0.30